President Biden signed 10 new executive orders on his second day in office that are designed to help roll out his broader plan to fight COVID-19.

“Our national strategy is comprehensive – it’s based on science, not politics; it’s based on truth, not denial,” Mr. Biden said. He also promised to restore public trust, in part by having scientists and public health experts speak to the public.

New administration, new strategy to fight COVID-19 pandemic

BY ALICIA AULT

President Biden signed 10 new executive orders on his second day in office that are designed to help roll out his broader plan to fight COVID-19.

“For the past year, we couldn’t rely on the federal government to act with the urgency and focus and coordination we needed, and we have seen the tragic cost of that failure,” Mr. Biden said in remarks from the White House, unveiling his 198-page National Strategy for the COVID-19 Response and Pandemic Preparedness.

He said in a press briefing on Jan. 21 that as many as 500,000 Americans will have died by February. “It’s going to take months for us to turn things around,” he said.

“Our national strategy is comprehensive – it’s based on science, not politics; it’s based on truth, not denial,” Mr. Biden said. He also promised to restore public trust, in part by having scientists and public health experts speak to the public.

“Thats why you’ll be hearing a lot more from Dr. Fauci again, not from the president,” he said, adding that the experts will be “free from political interference.”

While the president’s executive orders can help accomplish some of the plan’s proposals, the majority will require new funding from Congress and will be included in the $1.9 trillion American Rescue Plan.
Anaphylaxis after COVID-19 vaccine rare but rising

BY KERRY DOOLEY YOUNG

Health care providers should be ready to treat rare cases of anaphylaxis following administration of COVID-19 vaccines, federal medical officials have urged. The officials also stressed the importance of continuing vaccinations, despite reports of the rare side effect.

There have been 29 cases of anaphylaxis to date following administration of a COVID-19 vaccine, officials from the Centers for Disease Control and Prevention said in a call with reporters on Jan. 6.

The severe allergic reaction, which appears to be rare, can happen with either the Pfizer-BioNTech vaccine or the rival Moderna product. The Food and Drug Administration granted emergency-use authorizations for these two vaccines in December 2020.
Even with the cases seen to date, the COVID-19 vaccines remain a "good value proposition," Nancy Messonnier, MD, director of the CDC’s National Center for Immunization, said in the call.

There have been about 11.1 cases of anaphylaxis per million doses with the Pfizer-BioNTech COVID-19 vaccine, which is higher than the estimated 1.3 cases per million doses with influenza vaccines, she said. But she said the low risk of anaphylaxis must be balanced against the threat of COVID-19, which currently claims about 3,000 lives a day in the United States. In addition, many people are reporting long-term complications with COVID-19 even if they recover.

Kept in context, the data on anaphylaxis should not scare people away from getting a COVID-19 vaccine, she added.

"Their risk from COVID and poor outcomes is still more than the risk of a severe outcome from the vaccine," Dr. Messonnier said. "And fortunately, we know how to treat anaphylaxis."

Dr. Messonnier urged health care workers administering COVID-19 vaccines to be prepared.

"Anybody administering vaccines needs not just to have the EpiPen available, but frankly, to know how to use it," Dr. Messonnier said.

MMWR details
The CDC on Jan. 6 also provided an update on anaphylaxis in Morbidity and Mortality Weekly Report.

The information included in the report was based on cases reported with the Pfizer-BioNTech vaccine—the first to get emergency-use authorization from the FDA. On the call with reporters, CDC officials confirmed there have been additional reports since then and anaphylaxis has been reported with both the Pfizer-BioNTech and Moderna vaccines. CDC officials said they could not give a breakdown of how many cases were linked to each of these products at this time.

Between Dec. 14 and 23, 2020, monitoring by the Vaccine Adverse Event Reporting System detected 21 cases of anaphylaxis after administration of a reported 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine. Most reactions—71%—occurred within 15 minutes of vaccination.

A version of this article originally appeared on Medscape.com.
can Rescue package that Mr. Biden hopes legislators will approve.

Ten new orders
The 10 new pandemic-related orders Mr. Biden signed on Jan. 21 follow 2 he signed on his first day in office.

One establishes a COVID-19 Response Office responsible for coordinating the pandemic response across all federal departments and agencies and also reestablishes the White House Directorate on Global Health Security and Biodefense, which was disabled by the Trump administration.

The other order requires masks and physical distancing in all federal buildings, on all federal lands, and by federal employees and contractors.

Among the new orders will be directives that:

• Require individuals to also wear masks in airports and planes, and when using other modes of public transportation including trains, boats, and intercity buses, and also require international travelers to produce proof of a recent negative COVID-19 test prior to entry and to quarantine after entry.

• Direct federal agencies to use all powers, including the Defense Production Act, to accelerate manufacturing and delivery of supplies such as N95 masks, gowns, gloves, swabs, reagents, pipette tips, rapid test kits, and nitrocellulose material for rapid antigen tests, and all equipment and material needed to accelerate manufacture, delivery, and administration of COVID-19 vaccine.

• Create a Pandemic Testing Board to expand supply and access, to promote more surge capacity, and to ensure equitable access to tests.

• Facilitate discovery, development, and trials of potential COVID-19 treatments, as well as expand access to programs that can meet the long-term health needs of those recovering from the disease.

• Facilitate more and better data sharing that will allow businesses, schools, hospitals, and individuals to make real-time decisions based on spread in their community.

• Direct the Education and Health & Human Services departments to provide schools and child-care operations guidance on how to reopen and operate safely.

• Direct the Occupational Safety and Health Administration to immediately release clear guidance for employers to keep workers safe and to enforce health and safety requirements.

The plan also sets goals for vaccination – including 100 million shots in the administration’s first 100 days. President Biden had already previewed his goals for vaccination, including setting up mass vaccination sites and mobile vaccination sites. During his remarks, Mr. Biden said that he had already directed the Federal Emergency Management Agency to begin setting up the vaccination centers.

The administration is also going to look into improving reimbursements for giving vaccines. As a start, the HHS will ask the Centers for Medicare & Medicaid Services to consider if a higher rate “may more accurately compensate providers,” according to the Biden plan.

“But the brutal truth is it will take months before we can get the majority of Americans vaccinated,” said Mr. Biden.

As part of the goal of ensuring an equitable pandemic response, the president will sign an order that establishes a COVID-19 Health Equity Task Force. The task force is charged with providing recommendations for allocating resources and funding in communities with inequities in COVID-19 outcomes by race, ethnicity, geography, disability, and other considerations.

Finally, the administration has committed to being more transparent and sharing more information. The national plan calls for the federal government to conduct regular, expert-led, science-based public briefings and to release regular reports on the pandemic. The administration said it will launch massive science-based public information campaigns – in multiple languages – to educate Americans on masks, testing, and vaccines, and also work to counter misinformation and disinformation.

The American Academy of Family Physicians applauded Mr. Biden’s initiative. “If enacted, this bold legislative agenda will provide much-needed support to American families struggling during the pandemic – especially communities of color and those hardest hit by the virus,” Ada D. Stewart, MD, AAFP president, said in a statement.

Dr. Stewart also noted that family physicians “are uniquely positioned in their communities to educate patients, prioritize access, and coordinate administration of the COVID-19 vaccine,” and urged the administration to ensure that family physicians and staff be vaccinated as soon as possible, to help them “more safely provide care to their communities.”

A version of this article originally appeared on Medscape.com.
Sleeping, more or less
A coauthor of that study, David Gozal, MD, FCCP, a pediatric pulmonologist and sleep medicine specialist at the University of Missouri in Columbia, said that the pandemic has had paradoxical effects on sleep patterns for many.

“At the beginning, with the initial phases of lockdown for COVID, for most of the people whose jobs were not affected and who did not lose their jobs, [for whom] there was not the anxiety of being jobless and financially strapped, but who now were staying at home, there was actually a benefit. People started reporting getting more sleep and, more importantly, more vivid dreams and things of that nature,” he said in an interview.

“But as the lockdown progressed, we saw progressively and increasingly more people having difficulty falling asleep or staying asleep, using more medicines such as hypnotics to induce sleep, and we saw a 20% increase in the overall consumption of sleeping pills,” he said.

Similar results were seen in a cross-sectional survey of 843 adults in the United Kingdom, which showed that nearly 70% of participants reported a change in sleep patterns, only 45% reported having refreshing sleep, and 46% reported being sleepier during lockdown than before. Two-thirds of the respondents reported that the pandemic affected their mental health, and one-fourth reported increased alcohol consumption during lockdown. Those with suspected COVID-19 infections reported having more nightmares and abnormal sleep rhythms (J Thorac Dis. 2020;12[Suppl 2]:S163-75).

It is possible that the effects of COVID-19 infection on sleep may linger long after the infection itself has resolved, results of a cohort study from China suggest. As reported in The Lancet (2021 Jan 8; doi: 10.1016/S0140-6736(20)32658-8), among 1,655 patients discharged from the Jin Yin-tan Hospital in Wuhan, China, 26% reported sleep disturbances 6 months after acute COVID-19 infection.

Self-medicating
Among 5,529 Canadians surveyed from April 3 through June 24, 2020, a large proportion reported the use of pharmacologic sleep aids (J Sleep Res. 2020 Nov 17; doi: 10.1111/jsr.13231), said Tetyana Kendzerska, MD, PhD, assistant professor of medicine in the division of respirology at the University of Ottawa.

“At the time of the survey completion, 27% of participants reported taking sleeping aids (prescribed or [over] the counter); across the entire sample, 8% of respondents reported an increase in the frequency of sleeping medication use during the outbreak compared to before the outbreak,” she said in an interview.

Many people resort to self-medicating with over-the-counter preparations such as melatonin and pain-relief nighttime formulations containing diphenhydramine (Benadryl), a first-generation antihistamine with sedative properties, noted Kannan Ramar, MBBS, MD, a critical care, pulmonary, and sleep medicine specialist at the Mayo Clinic in Rochester, Minn., and current president of the American Academy of Sleep Medicine.

“When people are self-medicating for what they think is difficulty sleeping, the concern is that even if a diagnosis of insomnia has been established, there could be another, ongoing sleep disorder that may be undiagnosed, which might be causing the problem with insomnia,” he said in an interview.

Causing concern
“For those people who have COVID, we have seen quite a few sleep issues develop. Those were not reported in the actual study, but in the clinic and subsequent studies published from other places,” Dr. Gozal said.

“People who suffered from COVID, and people who supposedly did very well and were virtually asymptomatic or maybe had only a headache or fever but did not need to go to the hospital, many of those people reported either excessive sleepiness for a long period of time, and would sleep 2 or 3 hours more per night. Or the opposite was reported: There were those that after recovering reported that they couldn’t sleep—they were sleeping 4 or 5 hours when they normally sleep 7 or 8,” he said.

It’s also unclear from current evidence whether the reported uptick in sleep problems is related to stress or, in patients who have had COVID-19 infections, to physiologic causes.

Dr. Gozal said that insomnia in the time of COVID-19 could be attributed to a number of factors such as less daily exposure to natural light from people sheltering indoors, stress related to financial or health worries, depression, or other psychological factors. It’s also, possible, however, that COVID-19–related physiological changes could contribute to sleep disorders, he said, pointing to a recent study in the Journal of Experimental Medicine (2021:218 [3]: e2020135) showing that SARS-CoV-2, the virus that causes COVID-19, can bind to neurons and cause metabolic changes in both infected and neighboring cells.

“There may be an increase in individuals who may require professional guidance to taper off from sleeping medications started or increased during the pandemic. While some of these sleep problems may be transient, it should be a high priority to ensure they do not evolve into chronic sleep disorders.”

Medications, even over-the-counter medications, all have side effects, and if one is taking a medication that has stimulants in place, such as pseudoephedrine in antihistamine combinations, that can potentially contribute to or exacerbate any underlying sleep disorders,” Dr. Ramar said.

Dr. Kendzerska recommended reserving medications such as melatonin, a chronobiologic therapy, for patients with sleep disorders related to circadian rhythm problems, including a sleep phase delay. Supplemental, short-term treatment with hypnotic agents such as zolpidem (Ambien), eszopiclone (Lunesta), or zaleplon (Sonata) should be used only as a last resort, she said.

Sleep medicine specialists recommend good sleep hygiene as the best means of obtaining restful sleep, including regular bed and wake times, limited exposure to stressful news (including COVID-19 stories), reduced consumption of alcohol and stimulants such as coffee or caffeine drinks, limited use of electronic devices in bed or near bedtime, and healthy lifestyle, including diet and exercise.

It is also foreseeable that there may be an increase in individuals who may require professional guidance to taper off from sleeping medications started or increased during the pandemic. While some of these sleep problems may be transient, it should be a high priority to ensure they do not evolve into chronic sleep disorders,” Dr. Kendzerska and colleagues wrote.

Affecting immunity
It has been well documented that, in addition to being, as Shakespeare called it, “the balm of hurt minds,” sleep has an important role in supporting the immune system.

“Sleep and immunity go together,” Dr. Ramar said. “When people have adequate sleep, their immune system is boosted. We know that there are good data from hepatitis A and hepatitis B vaccinations, and recently on flu vaccination, that if people get sufficient duration of sleep before and after they receive the shot, their likelihood of building an immune response to that particular vaccination tends to go up.”

Dr. Kendzerska said, “In our study, we did find that, among other factors, having a chronic illness was associated with new sleep difficulties during the pandemic. We did not look separately if sleep difficulties were associated with the COVID-19 infection or symptoms, but this is a great question to address with longitudinal data we have.”

Mitigating coronasomnia
All three sleep experts contacted for this article agreed that, for patients with insomnia, mitigating stress through relaxation techniques or cognitive-behavioral therapy is more beneficial than medication.

“Medications, even over-the-counter medications, all have side effects, and if one is taking a medication that has stimulants in place, such as pseudoephedrine in antihistamine combinations, that can potentially contribute to or exacerbate any underlying sleep disorders,” Dr. Ramar said.

“Mitigating coronasomnia” continued from page 1
**CARDIOLOGY**

**ACC guidance embraces new heart failure strategies**

BY TED BOSWORTH  
MDedge News

The newly updated expert consensus from the American College of Cardiology for management of heart failure with reduced ejection fraction includes several new guideline-directed medical therapies among other substantial changes relative to its 2017 predecessor.

The advances in treatment of heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction \( \leq 40\% \)) have resulted in a substantial increase in complexity in reaching treatment goals, according to the authors of the new guidance. Structured similarly to the 2017 ACC Expert Consensus Decision Pathway (J Am Coll Cardiol. 2018;71:201-30), the update accommodates a series of practical tips to bring all patients on board with the newer as well as the established therapies with lifesaving potential.

The potential return from implementing these recommendations is not trivial. Relative to an ACE inhibitor and a beta-blocker alone, optimal implementation of the current guideline-directed medical therapies (GDMT) “can extend medical survival by more than 6 years,” according to Gregg C. Fonarow, MD, chief of cardiology at the University of California, Los Angeles.

A member of the writing committee for the 2021 update, Dr. Fonarow explained that the consensus pathway is more than a list of therapies and recommended doses. The detailed advice on how to overcome the barriers to GDMT is meant to close the substantial gap between current practice and unmet opportunities for inhibiting HFrEF progression.

“Optimal GDMT among HFrEF patients is distressingly low, due in part to the number and complexity of medications that now constitute GDMT,” said the chair of the writing committee, Thomas M. Maddox, MD, executive director, Healthcare Innovation Lab, BJC HealthCare/Washington University, St. Louis. Like Dr. Fonarow, Dr. Maddox emphasized that the importance of the update for the practical strategies it offers to place patients on optimal care.

In the 2017 guidance, 10 pivotal issues were tackled, ranging from advice of how to put HFrEF patients on the multiple drugs that now constitute optimal therapy to when to transition patients to hospice care. The 2021 update covers the same ground but incorporates new information that has changed the definition of optimal care.

Perhaps most importantly, sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor (ARNI), and sodium-glucose transporter 2 (SGLT2) inhibitors represent major new additions in HFrEF GDMT. Dr. Maddox called the practical information about how these should be incorporated into HFrEF management represents one of the “major highlights” of the update.

Two algorithms outline the expert consensus recommendations of the order and the dose of the multiple drugs that now constitute the current GDMT. With the goal of explaining exactly how to place patients on all the HFrEF therapies associated with improved outcome, “I think these figures can really help us in guiding our patients to optimal medication regimens and dosages,” Dr. Maddox said. If successful, clinicians “can make a significant difference in these patients’ length and quality of life.”

Most cardiologists and others who treat HFrEF are likely aware of the major improvements in outcome documented in large trials when an ARNI and a SGLT2 inhibitor were added to previously established GDMT, but the update like the 2017 document is focused on the practical strategies of implementation, according to Larry A. Allen, MD, medical director of advanced heart failure at the University of Colorado at Denver, Aurora.

“The 2017 Expert Consensus Decision Pathway got a lot of attention because it takes a very practical approach to questions that clinicians and their patients have to tackle everyday but for which there was not always clear answers from the data,” said Dr. Allen, a member of the writing committee for both the 2017 expert consensus and the 2021 update. He noted that the earlier document was one of the most downloaded articles from the ACC’s journal in the year it appeared.

“There is excellent data on the benefits of beta-blockers, ARNI, mineralocorticoid antagonists, and SGLT2 inhibitors, but how does one decide what order to use them in?” Dr. Allen asked in outlining goals of the expert consensus.


**VIEW ON THE NEWS**

Jonathan Ludmir, MD, comments: The ACC 2021 Expert Consensus Decision Pathway successfully and succinctly highlights all of the key features of how to successfully provide comprehensive GDMT for HFrEF patients. In addition to optimizing GDMT, early referral to heart failure specialists and consideration of advanced therapies is critical. I hope initiation of GDMT will not be delayed. Physicians should feel empowered to initiate GDMT in HFrEF patients in order to avoid care delays. I hope it can be effectively distributed and implemented by all health care providers managing heart failure patients.

---

**Fatigue, insomnia plague survivors of severe COVID-19**

BY RICHARD FRANKI  
MDedge News

Three-quarters of patients hospitalized with COVID-19 were still experiencing at least one symptom of the infection 6 months after being discharged, according to a follow-up study involving 1,733 patients.

“Patients with COVID-19 had symptoms of fatigue or muscle weakness, sleep difficulties, and anxiety or depression,” and those with “more severe illness during their hospital stay had increasingly impaired pulmonary diffusion capacities and abnormal chest imaging manifestations,” Chaolin Huang, MD, of Jin Yin-tan Hospital in Wuhan, China, and associates wrote in The Lancet (2021 Jan 8. doi: 10.1016/S0140-6736(20)32656-8).

Fatigue or muscle weakness, reported by 63% of patients, was the most common symptom, followed by sleep difficulties, hair loss, and smell disorder. Altogether, 76% of those examined 6 months after discharge from Jin Yin-tan Hospital — the first designated for patients with COVID-19 in Wuhan — reported at least one symptom, they said. Symptoms were more common in women than men: 81% vs. 73% had at least one symptom, and 66% vs. 59% had fatigue or muscle weakness, the investigators said.

Note: Based on followup data for 1,733 patients discharged from Jin Yin-tan Hospital in Wuhan, China, between Jan. 7 and May 29, 2020.

Source: Lancet 2021 Jan 8. doi: 10.1016/S0140-6736(20)32656-8
This advertisement is not available for the digital edition.
Screening paused during pandemic concerns

BY JIM KLING
MDedge News

FROM THE JOURNAL CHEST®*

The COVID-19 pandemic led to a drastic reduction in lung cancer screening, but the rate of decline was similar between Whites and non-Whites and between rural and nonrural populations. All groups saw their rates of lung cancer screening (LCS) return to near prepandemic levels by June 2020, according to a new analysis of two academic and two community imaging sites in North Carolina.

The study was led by Louise Henderson, PhD, of the Lineberger Comprehensive Cancer Center, and M. Patricia Rivera, MD, FCCP, of the department of medicine, division of pulmonary disease and critical care medicine, both at the University of North Carolina at Chapel Hill. The findings appeared online in Chest (2021 Jan 5. doi: 10.1016/j.chest.2020.12.033).

“I am [not] surprised by the decline, but I am certainly reassured,” Dr. Begnaud said. Although she hasn’t seen a similar decline yet, Dr. Begnaud expects it’s coming. “I think we’ll see a major decline even throughout this year on lung cancer screening as well. You might have seen higher numbers after that,” said Dr. Begnaud.

The current winter surge in cases is likely to have long-lasting impact on lung cancer screening as well. Although she hasn’t seen a similar decline yet, Dr. Begnaud expects it’s coming. “I think we’ll see a major decline even throughout this year in screening until we are squarely out of the pandemic.” Things could be particularly challenging for resource-poor settings. “If physical resources (CT scanners) and human resources (techs, radiologists, primary care providers) are overworked, they may not have the bandwidth for ‘elective’ and preventive care,” said Dr. Begnaud.

Two previous studies looked at changes in lung cancer screening after the onset of the pandemic, but neither examined patient characteristics or risk factors. The current study included 3,688 screening exams (52.3% first-time exams), and divided them up into the pre-COVID-19 era (Jan. 1 to March 2, 2019), the beginning of the pandemic (March 3 to March 29, 2020), the shutdown period (March 30 to May 21, 2020) and the ramp-up period (May 22 to Sept. 30, 2020).

The largest reduction of screening volume occurred during the beginning of the pandemic, at –33.6% (95% confidence interval, –11.9% to –55.3%). By June, the reduction in volume was –9.1%, compared with pre-COVID-19 levels (95% CI, –4.7% to –23.0%). In the period between June and September 2020, the overall rate was similar to pre-COVID-19 levels (–15.3% change; 95% CI, –7.8% to 38.4%).

The researchers found no differences in screening changes among patient groups based on age, sex, race, smoking status, body mass index, COPD status, hypertension, or patient residence. The proportion of exams that were first-time screens was highest before the pandemic (53.8%), and declined at the beginning of the pandemic (50.7%), during shutdown (49.7%), and during the ramp-up period (48.6%). The difference between the prepandemic and ramp-up period in terms of first-time screens was statistically significant (P = .0072).

The investigators offered a couple of caveats: “Our results do not demonstrate differences in LCS volumes pre-versus during COVID among non-White patients or rural patients, both of which have persistently experienced disparities in lung cancer outcomes and other cancer screening modalities. Additionally, our results do not suggest that patients at high risk of COVID...”
LUNG CANCER

NSCLC deaths continue to drop, driving down national cancer mortality rates

BY PAM HARRISON

F or the second year in a row, mortality from cancer has fallen in the United States, driven largely by reductions in the incidence of, and death from, non–small cell lung cancer (NSCLC) in men and women, according to a new report from the American Cancer Society.

The study was published online Jan. 12 in CA: A Cancer Journal for Clinicians (doi: 10.3322/ caca.21654).

“Mortality rates are a better indicator of progress against cancer than incidence or survival because they are less affected by biases resulting from changes in detection practices,” wrote the authors, led by Rebecca Siegel, MPH, American Cancer Society, Atlanta.

“The overall drop of 31% as of 2018 [since the early 1990s] translates to an estimated 3,188,500 fewer cancer deaths (2,170,700 in men and 1,017,800 in women) than what would have occurred if mortality rates had remained at their peak,” the researchers added.

Lung cancer accounted for 46% of the total decline in cancer mortality in the past 5 years, with a record, single-year drop of 2.4% between 2017 and 2018.

The recent and rapid reductions in lung cancer mortality reflect better treatments for NSCLC, the authors suggested. For example, survival rates at 2 years have increased from 34% for patients diagnosed with NSCLC between 2009 and 2010 to 42% for those diagnosed during 2015 and 2016 – an absolute gain of 5%-6% in survival odds for every stage of diagnosis.

On a more somber note, the authors warned that COVID-19 is predicted to have a negative impact on both the diagnosis and outcomes of patients with cancer in the near future.

“We anticipate that disruptions in access to cancer care in 2020 will lead to downstream increases in advanced stage diagnoses that may impede progress in reducing cancer mortality rates in the years to come,” Ms. Siegel said in a statement.

New cancer cases

The report provides an estimated number of new cancer cases and deaths in 2021 in the United States (nationally and state-by-state) based on the most current population-based data for cancer incidence through 2017 and for mortality through 2018. “An estimated 608,570 Americans will die from cancer in 2021, corresponding to more than 1600 deaths per day,” Ms. Siegel and colleagues reported.

The greatest number of deaths are predicted to be from the most common cancers: Lung, prostate, and colorectal cancer in men and lung, breast, and colorectal cancer in women, they added. However, the mortality rates for all four cancers are continuing to fall.

As of 2018, the death rate from lung cancer had dropped by 54% among males and by 30% among females over the past few decades, the investigators noted.

Mortality from female breast cancer has dropped by 41% since 1989; by 52% for prostate cancer since 1993; and by 53% and 59% for colorectal cancer for men (since 1980) and women (since 1969), respectively.

“However, in recent years, mortality declines have slowed for breast cancer and colorectal cancer and have halted for prostate cancer,” the researchers noted.

In contrast, the pace of the annual decline in lung cancer mortality doubled among men from 3.1% between 2009 and 2013 to 5.5% between 2014 and 2018, and from 1.8% to 4.4% among women during the same time intervals.

Increase in incidence at common sites

Despite the steady progress in mortality for most cancers, “rates continue to increase for some common sites,” Ms. Siegel and colleagues reported.

For example, death rates from uterine corpus cancer have accelerated from the late 1990s at twice the pace of the increase in its incidence. Death rates also have increased for cancers of the oral cavity and pharynx – although in this cancer, increases in mortality parallel an increase in its incidence.

“Pancreatic cancer death rates [in turn] continued to increase slowly in men ... but remained stable in women, despite incidence [rates] rising by about 1% per year in both sexes,” the authors observed.

Meanwhile, the incidence of cervical cancer, although declining for decades overall, is increasing for patients who present with more distant-stage disease as well as cervical adenocarcinoma, both of which are often undetected by cytology.

“These findings underscore the need for more targeted efforts to increase both HPV [human papillomavirus] vaccination among all individuals aged [26 and younger] and primary HPV testing or HPV/cytology co-testing every 5 years among women beginning at age 25,” the authors emphasized.

On a more positive note, the long-term increase in mortality from liver cancer has recently slowed among women and has stabilized among men, they added.

Once again, disparities in both cancer occurrence and outcomes varied considerably between racial and ethnic groups. For example, cancer is the leading cause of death in people who are Hispanic, Asian American, and Alaska Native. Survival rates at 5 years for almost all cancers are still higher for White patients than for Black patients, although the disparity in cancer mortality between Black persons and White persons has declined to 13% from a peak of 33% in 1993.

Geographic disparities in cancer mortality rates still prevail; the rates are largest for preventable cancers such as lung and cervical cancer, for which mortality varies by as much as fivefold across states. And although cancer remains the second most common cause of death among children, death rates from cancer have continuously declined over time among both children and adolescents, largely the result of dramatic declines in death rates from leukemia in both age groups.

The study authors have disclosed no relevant financial relationships.

A version of this article originally appeared on Medscape.com.
ANNUAL AWARDS
Master FCCP
Nancy A. Collop MD, Master FCCP

College Medalist Award
Neil R. MacIntyre, MD, FCCP

Distinguished Service Award
Lisa K. Moorest, MD, FCCP

Master Clinician Educator
William F. Kelly, MD, FCCP
David A. Schulman, MD, MPH, FCCP

Early Career Clinician Educator
Subani Chandra, MD, FCCP

Alfred Soffer Award for Editorial Excellence
Barbara Anderson, CHEST Staff
Laura Lipsky, CHEST Staff

Presidential Citation
Mangala Narasimhan, DO, FCCP
Renli Qiao, MD, PhD, FCCP

HONOR LECTURE AND MEMORIAL AWARDS
Edward C. Rosenow III, MD, Master FCCP/Master Teacher Ended Honor Lecture
Raising the Bar: The Interventional Pulmonary Outcomes Group
Lonny B. Yarmus, DO, FCCP

Roger C. Bone Memorial Lecture in Critical Care
To SIRS with Love: Dr. Roger Bone’s Continued Influence on Early Sepsis Care
Emanuel P. Rivers, MD, MPH, FCCP

Murray Kornfeld Memorial Founders Lecture
Our Pneumonia Journey: The Lung and Beyond
Marcos I. Restrepo, MD, PhD, FCCP

CHEST FOUNDATION GRANT AWARDS

The GlaxoSmithKline Distinguished Scholar in Respiratory Health
Gupta, MD, FCCP
Cytokine Release in SARS COV2 Viral Illness and Trends of Inflammation in Acute Respiratory Distress Syndrome Manifestations and Management

This grant is supported by an endowed fund from GlaxoSmithKline.

CHEST Foundation and the Alpha-1 Foundation Research Grant in Alpha-1 Antitrypsin Deficiency
Paul R. Ellis, MBChB
Cardiovascular Outcomes and Phenotypes in Pulmonary Exacerbations of Alpha-1 Antitrypsin

This grant is jointly supported by the CHEST Foundation and the Alpha-1 Foundation.

CHEST Foundation Research Grant in Women’s Lung Health
Shannon E. Kay, MD
Sex-specific Gene Expression in Asthma

This grant is supported by the CHEST Foundation.

CHES Foundation Research Grant in Chronic Obstructive Pulmonary Disease
Davide Biondini, MD, PhD
Role of the Immune Check Points (CTLA-4 and PD-1) in the Development or Evasion of Smoking-Induced Chronic Obstructive Pulmonary Disease

Andrew J. Gangemi, MD
Are Sleep Health, Nicotine Metabolism, and Airway Inflammation Mechanisms for Differences in Lung Function between African American and Non-Hispanic White Smokers? A Proof-of-Concept Examination

These grants are supported by AstraZeneca LP.

CHEST Foundation Research Grant in Critical Care
Mounica Vallurupalli, MD
Evaluating the Impact of Clonal Hematopoesis on Host Immune Response During Sepsis

This grant is supported by the CHEST Foundation.

CHEST Foundation Research Grant in Lung Cancer
Stefanie Mason, MD
Implications of Longitudinal Muscle-Mass Trajectories in Lung Cancer

This grant is supported by the CHEST Foundation.

CHEST Foundation Research Grant in Venous Thromboembolism
Jansen N. Scheult, MD, MBChB
Untangling the NET: Neutrophil Activation as the Driver of Venous Thromboembolism in Coronavirus Disease 2019

This grant is supported by the CHEST Foundation.

CHEST Foundation Research Grant in Nontuberculous Mycobacteria Diseases
Bryan A. Garcia, MD
Longitudinal Proteomic Endotyping of Patients with Nontuberculous Mycobacterial Lung Infections

This grant is supported by Insmed Incorporated.

CHEST Foundation Research Grant in Cystic Fibrosis
Jeffrey Barry, MD
Eosinophilia as a Biomarker for Worse Outcomes in Cystic Fibrosis

Kristina Montemayor, MD
The Association of Sex Hormones and Respiratory Morbidity in Individuals with Cystic Fibrosis

These grants are supported by Vertex Pharmaceuticals.

John R. Addrizzo, MD, FCCP Research Grant in Severe Asthma
Changwan Ryu, MD
Extracellular Matrix Proteins as a Biomarker for Stage IV Sarcoidosis

This grant is in honor of John R. Addrizzo, MD, FCCP and is jointly supported by the Addrizzo family and the CHEST Foundation.

CHEST Foundation Research Grant in Pulmonary Fibrosis
Sarah Beshay, MD
COPA Syndrome-Associated Mutations in Lung Transplant Recipients for Pulmonary Fibrosis

Erica D. Farrant, MD
The Future of Telehealth in Intestinal Lung Disease

These grants are supported by Boehringer Ingelheim Pharmaceuticals and Genentech, Inc.

CHEST Foundation Research Grant in Sleep Medicine
Tetyana Kendzerska, MD, PhD
The Role of Sleep and Circadian Disturbances in Cancer Development and Progression: A Historical Multi-center Clinical Cohort Study

Nancy Stewart, DO
Improving COPD/OSA Overlap Syndrome Pre-Discharge Care Delivery

These grants are funded by Jazz Pharmaceuticals, Inc.

CHEST Foundation and Association of Critical Care Medicine Program Directors Award Research Grant in Medical Education
Ilana R. Krumm, MD
What’s good about Soul Food? Discovering and Analyzing Elements of an ICU Team Group Discussion Which Improve Provider Wellness

This grant is jointly supported by the CHEST Foundation and APC-CMPD.

CHEST Foundation and American Thoracic Society Research Grant in Diversity
Thomas S. Valley, MD, MSc
Understanding Differences in Delivery of Care Processes for Respiratory Failure by Race/Ethnicity

This grant is jointly supported by
the CHEST Foundation and ATS.

CHEST Foundation Research Grant in COVID-19
David Furfaro, MD
Subphenotypes, Inflammatory Profiles, and Antibody Response in COVID-19 ARDS
This grant is supported by the CHEST Foundation.

CHEST Foundation and American Thoracic Society Grant in COVID-19 and Diversity
Peter D. Jackson, MD
The Effect of the COVID-19 Pandemic on Tuberculosis Care in Uganda
This grant is jointly supported by the CHEST Foundation and ATS.

CHEST Foundation Research Grant in Ultrasonography and COVID-19
Marjan M. Islam, MD
Thoracic Ultrasound in COVID-19: A Prospective Study Using Lung and Diaphragm Ultrasound in Evaluating Dyspnea in ICU Survivors with COVID-19 in a Post-ICU Clinic
This grant is jointly supported by the CHEST Foundation and FUJIFILM SonoSite.

Siddharth Dugar, MBBS
Spontaneous Echo Contrast in Lower Extremity and Correlation with Venous Velocity and Subsequent Deep Venous Thrombosis in Critically Ill COVID-19 Patients
This grant is jointly supported by the CHEST Foundation and FUJIFILM SonoSite.

CHEST Foundation Community Service Grant Honoring D. Robert McCaffree, MD, Master FCCP
Ivan Nemorin, MBA, MS, RRT
Healthier Homes for Children-Community Asthma Prevention Program
Joseph Huang, MD
East Africa Training Initiative (EATI)

Aninda Das, MD, MBBS
Screening for Childhood Tuberculosis in Children 0-4 years of Age with Moderate to Severe Malnutrition in a Rural District of West Bengal, India
Trishual Siddharthan, MD
Establishing a Pulmonary and Critical Care Training Program in Uganda
Marina Lima, MD, MSc
Asmaland: The First Gamified Pediatric Asthma Educational Program in Portuguese
Roberta M. Kato, MD
Lung Power
These grants are supported by the CHEST Foundation.

Alfred Soffer Research Award Winners
Mazen O. Al-Qadi, MD: Respiratory variation in right atrial pressure predicts right ventricular dysfunction in patients with pre-capillary pulmonary hypertension
Valerie G. Press, MD: Cost saving simulation for the transition from nebulizer to combination of nebulizer and metered-dose inhalers (MD)

Young Investigator Award Winners
Gabriel E. Ortiz Jaimes, MD: Correlation of cardiac output measurement by goal-directed echocardiography performed by intensivists vs pulmonary artery catheter
Palakkumar Patel, MD: Impact of having pulmonary hypertension in patients admitted with acute exac-
Bronchiolitis: Rare diseases, diagnostic challenges, and few proven therapies

BY BRIAN R. POOLE, MD, AND SEAN J. CALLAHAN, MD

What’s in a name?
Bronchiolitis, a group of diseases also referred to as “small airways diseases,” is characterized by inflammation and/or fibrosis in airways less than 2 mm in diameter. In pediatric patients, it is most commonly related to acute viral infections, while in adults, it is often associated with chronic diseases. Bronchiolitis is a well-recognized complication in a significant number of patients who have undergone lung or stem cell transplantation. Common associations also include connective tissue diseases, environmental or occupational inhalation exposures, aspiration, drug toxicity, and infections. Diagnosing bronchiolitis can be challenging for clinicians, and few treatment options exist apart from treating identifiable underlying etiologies. More research is needed into noninvasive diagnostic techniques and treatment modalities.

The terminology used to describe bronchiolitis has evolved over time. Bronchiolitis is now used to describe conditions where the primary pathologic condition is damage to the bronchiolar epithelium not attributable to a larger parenchymal disease (such as hypersensitivity pneumonitis). This change in nomenclature explains why the condition for which the term “bronchiolitis obliterans organizing pneumonia” (BOOP) is now simply recognized as “organizing pneumonia.” Despite several proposed classification schemes focusing on histopathology, there is no consensus regarding the different subtypes of bronchiolitis, leading to confusion in some cases. Recently, authors have attempted to distinguish cases based on three main histologic patterns (Urisman A, et al. Surg Pathol Clin. 2020;13[1]:189).

- **Obliterative/constrictive bronchiolitis** (OB) – the terms “obliterative” and “constrictive” are used interchangeably throughout pulmonary literature. It is characterized by fibroblast-rich tissue accumulation in the subepithelium of bronchioles leading to progressive narrowing of the lumen. In addition to the transplant setting, it is often seen in patients with rheumatoid arthritis or other connective tissue diseases, inhalational exposures, or acute respiratory infections. More recently, clinicians have recognized diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) as a rare condition causing OB with potentially effective treatment.
- **Follicular bronchiolitis** (FB) – features peribronchiolitis inflammation with subepithelial lymphoid deposits leading to luminal obstruction. FB is chiefly associated with conditions of impaired immunity or chronic airway infection, such as autoimmune connective tissue diseases (especially rheumatoid arthritis and Sjögren’s), severe combined immunodeficiency, HIV, cystic fibrosis, and primary ciliary dyskinesia.
- **Diffuse panbronchiolitis** (DBP) – features bilateral bronchiolar lesions with lymphocytic inflammation of the bronchiolar wall, as well as peribronchial inflammation and accumulation of interstitial foamy macrophages. Patients afflicted with DBP may suffer repeated bacterial colonization or infection. There is a higher prevalence of DBP in Asia where it was first identified in the 1960s, potentially due to several HLA alleles that are more common in Asia. In addition to the above terminology, the transplant-setting diagnosis “bronchiolitis obliterans syndrome” (BOS) is used to denote progressive obstructive lung disease for which there is not another cause aside from chronic graft rejection. For these patients, clinicians assume the underlying disease entity is OB, but they often lack histopathologic confirmation.

Diagnosis is challenging
Symptoms of bronchiolitis are typically dyspnea and cough, and patients may often be diagnosed with asthma or COPD initially. Pulmonary function testing may show signs of obstruction, restriction, or mixed disease with or without a reduction in DLco. Chest radiography often appears normal, but high-resolution CT may show expiratory air trapping and centrilobular nodules. Advanced imaging modalities may augment or replace CT imaging in diagnosing bronchiolitis; investigators are evaluating pulmonary MRI and fluoroscopy with computerized ventilation analysis in clinical trials (NCT04080232).

Currently, open or thorascopic lung biopsy is typically required to make a definitive diagnosis. Because bronchiolitis is a patchy and heterogeneous process, transbronchial biopsy may provide insufficient yield, with a sensitivity of 29% to 70%.
When patients are chronically and critically ill, they often need continued care after their stay in an intensive or critical care unit. With physician-led acute-level care, Kindred Hospitals offer the extended recovery time these patients need to reach their potential.

Extended recovery times only matter when you take advantage of that time. Our Early Progressive Mobility Program works to help liberate our ventilator patients by incorporating movement into their therapy routines as quickly as possible.

Our ICU/CCU-level staffing and specially trained caregivers work together to improve outcomes, reduce costly readmissions and help patients progress to a lower level of care.

If you have patients who can benefit from aggressive, specialized care for an extended recovery time, learn more at recoveratkindred.com.
In the year of COVID-19, we saw unprecedented changes in our environment and social interactions. Almost nothing was as it should be—sports championships in a “bubble,” social distancing, limited travel, economic hardships, and, of course, the devastating effects on the health of people all over the world. CHEST did not shy away from the challenges of COVID-19. Instead, we accelerated our focus on education, patient care, research, and advocacy to assist clinicians caring for affected patients. The CHEST Foundation, the philanthropic arm of CHEST, contributed to this effort by funding research and community service grants and distributing over 14,000 pieces of PPE to health workers and the public.

Amid social protests, CHEST issued statements supporting inclusion and diversity and called for improving health care disparities. To better understand these important issues, the CHEST Foundation began conducting listening tours across the country to learn what is important to patients and what barriers they face. These lessons will influence how the foundation implements its current programs and designs future programs. Over the next few months, the CHEST Foundation will set in motion a course of action to support valuable programs in these areas. We will focus on three main themes.

First, we will utilize the strength of CHEST by inviting fellows to participate in CHEST Foundation activities and serve on our committees. By creating an atmosphere of inclusion and collegiality, we believe that fellows will better understand the CHEST Foundation’s goals and commit themselves to strengthening the foundation for years to come.

Second, we want to establish relationships with organizations outside of CHEST. Although our partnerships with health care industry organizations are strong, we have few robust alliances in the non-endemic space. Corporations espouse wellness, and we have experts all over the world who can address the needs and concerns of these companies. Preliminary exploration tells us that non-endemic corporations have an interest in what we can offer.

Third, we want to grow the corpus of the CHEST Foundation. Dreams without funding become only aspirations, but dreams with funding become reality. Without a solid corpus, we operate on a short-term plan. CHEST has some of the most influential leaders in the fields of pulmonary, critical care, and sleep medicine. Together, we can develop programs that can significantly impact the lives of the people we serve.

The CHEST Foundation looks forward to building on past successes and tackling new challenges. On behalf of CHEST’s Board of Trustees and the gifted staff, I invite you to join us to reach these goals.

Continued from page 18

### Airways Disorders
Updated guidelines on the use of home O₂ in COPD: A much needed respite

The use of long-term oxygen therapy (LTOT, oxygen prescribed for at least 15 h/day) in patients with COPD and chronic hypoxemia has been standard of care based on trials from the 1980s that conferred a survival benefit with the use of continuous oxygen (Ann Internal Med. 1980;93[3]:391-8).


Based on a thorough systematic review of available literature, the committee made strong recommendations (moderate-quality evidence) for LTOT use in COPD with severe chronic resting hypoxemia (PaO₂ ≤ 55 mm Hg or SpO₂ ≤ 88%), conditional recommendations for the following: (1) Against LTOT use in COPD with moderate chronic resting hypoxemia [SpO₂ 89%-93% (low-quality evidence)]; (2) Ambulatory oxygen use in adults with COPD with severe exertional hypoxemia (moderate-quality evidence); and (3) Liquid oxygen use in patients who are mobile outside the home and require >3 L/min of continuous-flow oxygen during exertion (very-low-quality evidence). The review identified a dire need to develop a more robust evidence-based practice and incorporate shared decision-making while highlighting the deficit of conclusive data supporting supplemental oxygen for patients with exertional desaturation.

Kadambhari Vijaykumar, MD
Fellow-in-Training Member
Dharani Kumari Narendra, MBBS, FCCP
Steering Committee Member

### Clinical Pulmonary Medicine
COVID-19 vaccines – mRNA and beyond

We currently have two COVID-19 mRNA vaccines with US FDA emergency use authorization (EUA) for use in individuals less than or equal to age 18 years – Pfizer and Moderna. They work by introducing mRNA into a muscle cell that instructs the host cell ribosomes to express Sars-CoV-2 spike proteins, thereby triggering a systemic immune response.

Phase 3 trials demonstrated vaccine efficacy of 95% with both vaccines. Besides injection site pain, common side effects were fatigue, headache, chills, and myalgias, more frequent after dose two.

Both are two-dose regimens, with Pfizer’s 21 days apart and requires storage at -75 C, and Moderna’s 28 days apart, requiring storage at -20 C.

With reports of anaphylaxis reactions, CDC has issued a warning with a contraindication to the vaccine if there is severe allergic reaction after the first dose or a history of allergy to any of its components, including polyethylene glycol (PEG), or polysorbate, due to potential cross-reactive hypersensitivity with PEG.

Presently in development are three more vaccines. AstraZeneca (AZ) and Johnson & Johnson (JnJ) use an adenovirus vector. Both vaccines are stable at standard refrigerator temperatures. AZ’s results were mixed – with two, full-size doses efficacy at 62% effective, but with a half-dose followed by a full dose, efficacy was 90%. Novavax candidate works differently - it’s a protein subunit vaccine and uses a lab-made version of the SARS-CoV-2 spike protein, mixed with an adjuvant to help trigger the immune system. Results from all trials are eagerly awaited.

Mary Jo S. Farmer, MD, PhD, FCCP
Steering Committee Member
Shyam Subramanian, MD, FCCP
Chair

### What’s next for bronchiolitis?
While clinicians currently have few tools for diagnosing and treating these uncommon diseases, in the coming years, we should learn whether novel imaging modalities or less invasive procedures can aid in the diagnosis. Physicians hope these advances will preclude the need for invasive biopsies in more patients going forward. We should also learn whether newer, targeted agents like ruxolitinib are effective for BOS in patients with stem cell transplant. If so, this finding may open it and similar agents to investigation in other forms of bronchiolitis.

Dr. Poole and Dr. Callahan are with University of Utah Health, Salt Lake City, Utah.
An Unprecedented Year. An Unprecedented Impact.

In a year of uncertainty, the CHEST Foundation worked with donors, doctors, and patients to tackle some of the country’s most pressing issues.

Read the 2020 Impact Report to learn how we’re making a bigger than ever impact on the fight against lung disease.

READ THE REPORT
bit.ly/CHEST-Foundation-Impact-2020

Critical Care
Awake proning in COVID-19
Prone positioning has been shown to improve pulmonary mechanics in intubated patients with acute respiratory distress syndrome (ARDS). Proposed mechanisms for these benefits include shape matching, reversing the pleural pressure gradient, homogenizing distribution of pleural pressures, reducing the impact of the heart and abdomen on the lungs, and maintaining distribution of perfusion. Application of prone positioning has also been shown to reduce mortality in severe ARDS (Guérin, et al. N Engl J Med. 2013;368(23):2159-68). With the COVID-19 pandemic, clinicians have extrapolated that nonintubated patients with severe hypoxia may benefit from awake proning in the hopes of improving oxygenation and decreasing need for intubation. But, what’s the evidence so far? In small studies, awake proning has been shown to improve oxygenation (PaO2/FIO2 ratio) and work of breathing in patients with COVID-19 who were severely hypoxic and could tolerate proning receiving high flow nasal oxygen (HFNO) or noninvasive ventilation (Weatherald, et al. J Crit Care. 2021;61:63-70). However, other studies were less conclusive. In a study by Elharrar, et al (JAMA. 2020;323(22):2336-2338), oxygenation only improved in 25% of those who were proned, and this improvement was not sustained in half of patients after they were re-supined. Additionally, a recent prospective, observational study from Spain did not show benefit to awake proning in patients receiving HFNO with respect to need for intubation or risk of mortality (Ferrando, et al. Crit Care. 2020;24(1):597).

It remains unclear whether these
physiologic and short-term clinical benefits will prevent the need for mechanical ventilation and/or improve long-term outcomes, including mortality. The other nuances of application of prone positioning in spontaneously breathing patients, such as the optimal duration, positioning, clinical setting, termination criteria, and adverse effects will only become clearer with time and more robust studies. Currently, more than 60 studies examining the role of prone positioning in COVID-19 were enrolling or recently completed. Hopefully, more robust trials will provide evidence about the effectiveness of this therapy in this population. Finally, head over to CHEST’s COVID-19 Resource Center (https://www.chestnet.org/Guidelines-and-Resources/COVID-19/Resource-Center) to access a downloadable infographic describing the application of prone positioning.

Kathryn Pendleton, MD
Viren Kaul, MD
Steering Committee Members

Home-Based Mechanical Ventilation and Neuromuscular Disease
New horizons in home ventilation Phasing out a particular ventilator (Philips Respironics Trilogy 100 ventilator) has everyone on a steep learning curve with the replacement (Trilogy EVO). Most features are replicated in the EVO, including volume/pressure control and pressure-supported modes, mouthpiece ventilation, active/passive circuit capability, and portability (11.5 lb). Upgrades include longer battery life (13 hours), 7.5 hours internal/7.5 hours detachable) and use in pedi- atric patients now greater than or equal to 2.5 kg.


Other significant improvements include lower flow trigger sensitivity to accommodate patients with severe respiratory muscle weakness, a fast start AVAPS with rapid breath-to-breath 3 cm H₂O increases for the first minute to rapidly reach target tidal volume, and breath-to-breath auto-EPAP sensing of upper airway resistance to maintain upper airway patency for patients with upper airway obstruction. Internal Bluetooth transmission to cloud-based monitoring (Care Orches-trator™) expands access to patients without wi-fi or cellular service. New monitoring modules, SpO₂ and EtCO₂, and transcutaneous CO₂ monitoring (Sentec), transmit to cloud-based monitoring (EVO ECO₂, spring 2021).

These welcome improvements allow clinicians to better match ventilator settings to the patients’ evolving physiology and provide flexibility and connectivity to optimizelong-term care.

Karin Provost, DO, PhD
Steering Committee Member
Janet Hilbert, MD
NetWork Member

Online resources

Interprofessional Team
Interprofessional team approach to palliative extubation

The emotional burden of caring for patients at the end of life affects all members of the care team. Palliative (or compassionate) extubation consists of the withdrawal of mechanical ventilation when the absolute priority in care delivery is to afford comfort and allow for natural death to occur. Rapid withdrawal of ventilatory support may lead to significant respiratory distress, and the critical care team has an obligation to ensure patient comfort during the dying process (Truog RD, et al. Crit Care Med. 2008;36[3]:953). Registered nurses (RN) are primar-
This advertisement is not available for the digital edition.